Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal
antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in
patients with recurrent respiratory papillomatosis.
Phase:
Phase 2
Details
Lead Sponsor:
Centro de Investigación en. Enfermedades Infecciosas, Mexico